Amneal launches complex generic fluorometholone ophthalmic suspension

Bridgewater, n.j.--(business wire)--amneal pharmaceuticals, inc. (nasdaq: amrx) (“amneal” or the “company”) today announced the approval and launch of fluorometholone ophthalmic suspension. the product received 180-day competitive generic therapy (cgt) exclusivity from the u.s. food and drug administration, a status that applies to first-marketed generics of key medicines. fml® suspension is indicated for the treatment of corticosteroid-responsive inflammation of the palpebral and bulbar conjun.
AMRX Ratings Summary
AMRX Quant Ranking